Publicacións (24) Publicacións de PABLO CABEZAS SAINZ

filter_list

2025

  1. CRISPR targeting of FOXL2 c.402C>G mutation reduces malignant phenotype in granulosa tumor cells and identifies anti-tumoral compounds

    Molecular Oncology, Vol. 19, Núm. 4, pp. 1092-1116

  2. Protamine-Based Nanotherapeutics for Gene Delivery to Glioblastoma Cells

    Molecular Pharmaceutics, Vol. 22, Núm. 5, pp. 2466-2481

  3. Red blood cell-tumor cell interactions promote tumor cell progression

    Journal of Experimental and Clinical Cancer Research, Vol. 44, Núm. 1

  4. Triazole-Derived Ruthenium(II) Complexes as Novel Candidates for Cancer Therapy

    ChemPlusChem, Vol. 90, Núm. 5

2024

  1. Targeting cancer stem cell OXPHOS with tailored ruthenium complexes as a new anti-cancer strategy

    Journal of Experimental and Clinical Cancer Research, Vol. 43, Núm. 1

  2. The Peptidoglycan Recognition Protein 1 confers immune evasive properties on pancreatic cancer stem cells

    Gut, Vol. 73, Núm. 9, pp. 1489-1508

2023

  1. Mitochondrial RNA methyltransferase TRMT61B is a new, potential biomarker and therapeutic target for highly aneuploid cancers

    Cell Death and Differentiation, Vol. 30, Núm. 1, pp. 37-53

  2. Severe neurometabolic phenotype in npc1−/− zebrafish with a C-terminal mutation

    Frontiers in Molecular Neuroscience, Vol. 16

2022

  1. In Vitro and In Vivo Biological Activity of Ruthenium 1,10-Phenanthroline-5,6-dione Arene Complexes

    International Journal of Molecular Sciences, Vol. 23, Núm. 21

  2. The structural conformation of the tachykinin domain drives the anti-tumoural activity of an octopus peptide in melanoma BRAFV600E

    British Journal of Pharmacology, Vol. 179, Núm. 20, pp. 4878-4896

2021

  1. Dysregulated splicing factor SF3B1 unveils a dual therapeutic vulnerability to target pancreatic cancer cells and cancer stem cells with an anti-splicing drug

    Journal of Experimental and Clinical Cancer Research, Vol. 40, Núm. 1

  2. Morphological abnormalities and gene expression changes caused by high incubation temperatures in zebrafish xenografts with human cancer cells

    Genes, Vol. 12, Núm. 1, pp. 1-12

  3. N-heterocyclic carbene iron complexes as anticancer agents: In vitro and in vivo biological studies

    Molecules, Vol. 26, Núm. 18

  4. Zftool: A software for automatic quantification of cancer cell mass evolution in zebrafish

    Applied Sciences (Switzerland), Vol. 11, Núm. 16

2020

  1. Circulating Tumor Cells Characterization Revealed TIMP1 as a Potential Therapeutic Target in Ovarian Cancer

    Cells, Vol. 9, Núm. 5

  2. Exploiting oxidative phosphorylation to promote the stem and immunoevasive properties of pancreatic cancer stem cells

    Nature Communications, Vol. 11, Núm. 1

  3. Looking for a better characterization of triple-negative breast cancer by means of circulating tumor cells

    Journal of Clinical Medicine, Vol. 9, Núm. 2

  4. Modeling Cancer Using Zebrafish Xenografts: Drawbacks for Mimicking the Human Microenvironment

    Cells, Vol. 9, Núm. 9

2019

  1. In vivo toxicity assays in zebrafish embryos: a pre-requisite for xenograft preclinical studies

    Toxicology Mechanisms and Methods, Vol. 29, Núm. 7, pp. 478-487

  2. POU1F1 transcription factor promotes breast cancer metastasis via recruitment and polarization of macrophages

    Journal of Pathology, Vol. 249, Núm. 3, pp. 381-394